(Q38335751)

2 September 2017

1 reference

title

Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes (English)

1 reference

2 September 2017

0 references

André J Scheen

1

1 reference

PubMed ID

25630605

2 September 2017

language of work or name

English

0 references

publication date

29 January 2015

1 reference

Expert Opinion on Drug Safety

2 September 2017

1 reference

2 September 2017

14

1 reference

2 September 2017

4

1 reference

2 September 2017

505-524

1 reference

A review of gliptins in 2011.

2 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

A review of gliptins for 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Saxagliptin overview: special focus on safety and adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Linagliptin: an update of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Safety of dipeptidyl peptidase 4 inhibitors: a perspective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

DPP-4 inhibitors: pharmacological differences and their clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Basal encephalocele in an adult patient presenting with minor anomalies: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Alogliptin benzoate for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Incretin-mimetic therapies and pancreatic disease: a review of observational data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Risk of pancreatitis in patients treated with incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Cardiovascular actions of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Cardiovascular effects of gliptins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Effects of alogliptin in chronic kidney disease patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Dipeptidyl peptidase-4: a key player in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1006625

10.1517/14740338.2015.1006625

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25630605